ERBB2 and inflammatory breast carcinoma: Since tumoral TLSs can promote more effective antitumor immunity [33, 34], and an active immune response is important for treatment of HER-2 + IBC, it was documented that many HER-2 + BCa patients are treated with chemotherapy and/or HER-2 targeted therapy and that some of the favorable effects are attributed to active antitumor immunity [35–37].